8-K current report · filed Jul 14, 2026

Syndax Pharmaceuticals Inc (SNDX) 8-K Current Report: July 14, 2026

Item 8.01Item EX-99.1Item EX-99.2SNDX overview

Short answer

Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). R&D event highlights late-stage programs and Syndax’s next R&D strategy chapter.

Syndax Pharmaceuticals Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • R&D event highlights late-stage programs and Syndax’s next R&D strategy chapter
  • New pipeline assets introduced, potentially broadening future growth opportunities
  • Press release and presentation dated July 14, 2026 provide detailed program updates and strategic context

Item EX-99.1 · Exhibit EX-99.1

  • New SNDX-4321 expands pipeline into EGFR-mutated NSCLC, targeting L858R, CNS metastases, atypical mutations, and acquired resistance
  • IND for SNDX-4321 expected by end-2026, with Phase 1 initiation planned for 2027
  • SNDX-62122 advances wholly owned next-generation menin inhibitor program into myelofibrosis, with IND and Phase 1 planned for 2027
  • Revumenib Phase 1/2 myelofibrosis proof-of-principle trial expected to begin 4Q26, with initial data targeted for 2H27
  • Axatilimab Phase 2 idiopathic pulmonary fibrosis topline data remain on track for 4Q26, providing a near-term pipeline catalyst

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation highlights two marketed drugs, Revuforj and Niktimvo, each annualizing at approximately $200M as of 1Q26
  • Syndax targets profitability while funding late-stage trials and pipeline expansion, improving visibility on near-term financing needs
  • Revumenib proof-of-principle myelofibrosis trial expected in 4Q26, with clinical activity validation anticipated in 2H27
  • Axatilimab Phase 2 IPF MAXPIRe topline data and Phase 2 cGVHD combination data expected in 4Q26
  • SNDX-62122 targets an IND submission in 2027, while SNDX-4321 expands the pipeline into mutant EGFR NSCLC

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Syndax Pharmaceuticals Inc 8-K filings

Get the next SNDX 8-K as it lands

Follow SNDX for push alerts, or ask the research agent what this filing means.